Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Kala Pharmaceuticals (KALA) Misses Q3 EPS by 1c
November 7, 2019 7:23 AM ESTKala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($0.68), $0.01 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $1.45 million versus the consensus estimate of $3.64 million.
INVELTYS demonstrated growing demand in the third quarter, with positive feedback from physicians and a... More
